N
Nanosphere
A molecular diagnostics platform for genomic and protein testing and analysis
About Nanosphere
Nanosphere operates in the biotechnology sector, specializing in advanced multiplex antibody assays and clinical diagnostics. The company serves a diverse range of clients, including academic researchers, clinical laboratories, and biodefense organizations. Nanosphere's core technology offers exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed, making it highly valuable for infectious disease testing and other clinical applications. The business model revolves around selling its proprietary diagnostic systems and consumables, generating revenue through both direct sales and long-term service agreements. The company's open architecture design allows for a wide variety of applications, enhancing its market reach and adaptability.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1999
- Headquarters
- Northbrook, United States
- Listing
- IPO 2007
- Employees
- 40
- Open positions
- None listed
- Dealroom signal
- 36.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, DNA, Genetics and genomics, Genome Engineering, Hard Tech, medical testing, proteomics
- Technology
- Deep Tech, Nanotech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Nanosphere.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | May 2016 | $77M | $77M | Luminex | — |
| POST IPO DEBT✓Debt | May 2015 | $4.1M | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $21M | 0% |
| 2025 | $21M | 0% |
| 2024 | $21M | 0% |
| 2023 | $21M | 0% |
| 2022 | $21M | 0% |
| 2021 | $21M | 0% |
| 2020 | $21M | — |
Growth signals
Latest recorded traffic for Nanosphere is 2K monthly website visits, down 4.8% over the last three months. Nanosphere's team declined 2.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Other known investors2 additional known investors
Luminex
Western Technology Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nanosphere on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nanosphere’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.